Skip to main content
. Author manuscript; available in PMC: 2019 Jan 2.
Published in final edited form as: Angew Chem Int Ed Engl. 2017 Nov 30;57(1):218–222. doi: 10.1002/anie.201710232

Figure 2.

Figure 2

a) A schematic illustration of the combination of PDT and RNT using 177Lu-PPNs-10nm. First, 177Lu-PPNs-10nm were introduced into the cells. After PPNs attached to mitochondria, the cells were exposed to 660 nm laser. The co-location of radionuclide and PDT reagent with the targeting subcellular organelle enhanced the radionuclide-based combination therapy. b) Cell viability of 4T1 cells treated with various concentrations of PPNs-10nm and 177Lu-PPNs-10nm with or without laser (660 nm). c) Measurement of the intracellular ROS levels by CellROX®Green. d) Confocal microscopy images of 4T1 cells incubated with PPNs and treated with commercial organelle trackers (Blue: Hoechst 33342; Green: MitoTracker® Green FM; Red: PPNs-10nm). e) Co-location analysis of PPNs-10nm and MitoTracker® Green FM. The white arrow indicated the overlay of PPNs-10nm and mitochondria.